Deal Covers Two Insulin Analogues for India
Key Highlights
- Mankind Pharma has entered into an exclusive agreement with China’s Chongqing Chenan Biopharmaceutical.
- The partnership covers in-licensing and marketing of two insulin analogue offerings in India.
- The agreement includes commercialisation of insulin degludec.
- It also covers insulin degludec as part of a combination therapy.
- The products are intended to strengthen Mankind Pharma’s injectable diabetes portfolio.
- Mankind Pharma expects the partnership to expand access to advanced diabetes therapies in India.
- The agreement forms part of the company’s strategy of accessing global innovation through partnerships.
- Mankind Pharma is also pursuing in-licensing opportunities to broaden its product portfolio.
New Delhi, August 20: Mankind Pharma Ltd has entered into an exclusive in-licensing and marketing agreement with China’s Chongqing Chenan Biopharmaceutical Co Ltd to commercialise two insulin analogue offerings in India, strengthening the Indian drugmaker’s presence in diabetes care.
The agreement covers insulin degludec and insulin degludec as part of a combination product, according to a company statement.
Mankind Pharma said the addition of the products would strengthen its injectable diabetes portfolio and help it address the evolving treatment requirements of patients in India.
Partnership targets diabetes care market
The agreement gives Mankind Pharma an opportunity to expand its presence in the country’s diabetes treatment market through advanced injectable therapies.
Insulin analogues are modified forms of insulin developed to provide specific absorption and duration characteristics, allowing physicians to tailor diabetes management according to patients’ requirements.
Insulin degludec is a long-acting insulin analogue used in diabetes management.
By adding the products to its portfolio, Mankind Pharma is seeking to build a more comprehensive presence within the injectable segment.
Exclusive commercialisation rights in India
The arrangement with Chongqing Chenan Biopharmaceutical is an exclusive in-licensing and marketing agreement for the Indian market.
Under licensing arrangements of this nature, pharmaceutical companies can bring products developed by external partners into specific markets while using their own commercial and distribution capabilities.
For Mankind Pharma, the agreement provides an avenue to expand its diabetes portfolio without relying solely on internally developed products.
Mankind looks to expand access
Mankind Pharma Senior President for Sales and Marketing Atish Majumdar said the partnership reinforces the company’s commitment to expanding access to advanced therapies for patients in India.
He said it would also further strengthen Mankind Pharma’s presence in the injectable diabetes segment.
India represents a significant market for diabetes treatment, creating demand for a broad range of oral and injectable therapies.
Global innovation through partnerships
Mankind Pharma said the agreement is aligned with its broader strategy of leveraging global innovation through strategic partnerships and in-licensing opportunities.
Such arrangements allow pharmaceutical companies to access therapies developed internationally and combine them with established domestic sales, marketing and distribution networks.
The latest partnership also highlights continuing collaboration between Indian and overseas biopharmaceutical companies in bringing new treatment options to the Indian market.
Injectable portfolio set to expand
The addition of the insulin analogue products is expected to give Mankind Pharma a broader offering for healthcare professionals and patients managing diabetes.
The company said the products would contribute to a more comprehensive portfolio while reinforcing its commitment to addressing changing patient needs.
The partnership is also expected to support Mankind Pharma’s broader efforts to expand its presence in chronic therapies and strengthen its position in the Indian pharmaceutical market.
